Glucose Control in Pre-Diabetic Renal Transplant Patients
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Development of New-Onset Diabetes after Transplantation (NODAT) is common and serious
complication after kidney transplantation. Patients who develop NODAT are at increased risk
for loss of the transplanted organ and for diseases of the cardiovascular system.
It is believed that in many patients the development of overt NODAT is preceded by a phase of
impaired glucose tolerance that is called pre-diabetes.
This study aims at improving glucose metabolism in patients after kidney transplantation who
are in a pre-diabetic metabolic state. Patients who exhibit impaired glucose tolerance (IGT)
after kidney transplantation are randomized to either receive vildagliptin (Galvus),
pioglitazone(Actos) or placebo for three months.
The investigators hypothesize that treatment with vildagliptin or pioglitazone leads to
improved glycemic control compared to placebo.